Vaccines

Pfizer has launched a Phase 3 study of its RSV vaccine candidate and researchers at the George Washington University are studying the vaccine’s safety and ability to trigger an immune response in two groups of people at risk for severe illness caused by respiratory syncytial virus or RSV.

Julie E. Bauman, MD, MPH, director of the GW Cancer Center, associate dean of cancer and professor of medicine, was featured in the article “Cancer Vaccine Hunt Makes Progress, Finally,” by Lisa Jarvis in the Jan. 3 edition of the Washington Post. Bauman discussed the traction MRNA vaccine trials…

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1…

Cold and flu season is upon us, and this year respiratory syncytial virus, or RSV, has joined the COVID-19 variants as complicating factors. Learn how to tell the difference among them and what you can do to protect yourself.

The GW School of Medicine and Health Sciences is recruiting participants for the final stage of a clinical trial to evaluate two Omicron-specific vaccines. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious…

Two D.C.-area facilities are recruiting volunteers to test the efficacy of different doses of a monkeypox vaccine with the hope that they can stretch available supplies. The National Institutes of Health, in Bethesda, Maryland, and George Washington University, in D.C., are among eight locations…

Following the completion of its grant from the D.C. Department of Health, the George Washington University (GW) Medical Faculty Associates (MFA) COVID-19 Vaccine Center (GW Vaccine Center) discontinued its vaccination operations on Aug. 5, 2022.

The GW School of Medicine and Health Sciences has been selected to serve as one of 24 participating sites for the Phase 2 clinical trial to evaluate additional COVID-19 booster shots in adults, including multiple vaccines based on viral variants such as Delta and Omicron. The trial aims to…

David Diemert, MD, clinical director of the GW Vaccine Research Unit and professor of medicine at the George Washington University School of Medicine and Health Sciences discusses what scientists know about the Delta variant.

A vaccine for Lassa fever may be on the horizon, thanks to a new clinical trial jointly led by Elissa Malkin, DO, MPH, assistant research professor of medicine at the George Washington University School of Medicine and Health Sciences.